Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech is a promising company, with strong growth potential and a solid financial standing. Its preliminary financial results for 2025 show 3-5% YoY revenue growth, which is expected to increase to 13-17% in 2026. Additionally, the company has a diverse product portfolio that includes soft tissue repair and bone fusion products, which are in high demand in the surgical market. Furthermore, Sanara has secured a new contract with a major group purchasing organization, and plans to launch a new bone bioadhesive in 2027, further expanding its product offerings. Despite a recent net loss, the company's continuing operations have become profitable and management is focused on sustaining revenue growth and improving profitability in the future. With an EV/Revenue multiple of 3.0x and projected revenue for the next 12 months, Sanara MedTech's stock has a price objective of $36, making it a potential buy for investors.

Bears say

Sanara MedTech is facing financial challenges as the company has a high level of long-term debt compared to its available cash and borrowing capacity. Additionally, the company's revenue growth may be impacted in the near future as their key product, BIASURGE, received a contract from Vizient Inc. which will not take effect until January 1, 2026. Furthermore, the company's cash flows from operating activities are low and may not be able to support their operations in the near-term.

SMTI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Strong Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.